Literature DB >> 7679782

The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis.

Y Zhang1, D Burger, G Saruhan, M Jeannet, A J Steck.   

Abstract

In addition to myelin basic protein (MBP), other minor components of myelin, such as myelin-associated glycoprotein (MAG), may be important autoantigens in MS. To determine whether MAG might be involved in an autoimmune reaction in MS, we screened peripheral blood lymphocytes from MS patients and normal subjects for their sensitization to human MBP and MAG antigen using a [3H]thymidine incorporation assay. We recorded three patterns in MS patients: (1) patients who responded neither to MAG nor to MBP (4/11); (2) patients who responded to both MBP and MAG (5/11); and (3) patients who gave an exclusive response to MAG (2/11). The 10 healthy controls did not respond to either MAG or MBP. That some individuals with MS expressed a specific response against MAG and that more than 50% of MS patients expressed a sensitization to MAG suggest that MAG may have a role in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679782     DOI: 10.1212/wnl.43.2.403

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Constitutively hyposialylated human T-lymphocyte clones in the Tn-syndrome: binding characteristics of plant and animal lectins.

Authors:  K Mrkoci; S Kelm; P R Crocker; R Schauer; E G Berger
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

2.  Proteomic identification of immunoproteasome accumulation in formalin-fixed rodent spinal cords with experimental autoimmune encephalomyelitis.

Authors:  Mohit Raja Jain; Qing Li; Tong Liu; Joseph Rinaggio; Amit Ketkar; Vincent Tournier; Kiran Madura; Stella Elkabes; Hong Li
Journal:  J Proteome Res       Date:  2012-02-06       Impact factor: 4.466

Review 3.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.

Authors:  Joseph R Podojil; Mahesh V Padval; Stephen D Miller
Journal:  Cell Immunol       Date:  2011-05-31       Impact factor: 4.868

5.  Diversity and plasticity of self recognition during the development of multiple sclerosis.

Authors:  V K Tuohy; M Yu; B Weinstock-Guttman; R P Kinkel
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; R Milo; M B Lees; D Burger; C C Bernard; A Ben-Nun
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

7.  B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms.

Authors:  Joseph R Podojil; Linda N Liu; Shannon A Marshall; Ming-Yi Chiang; Gwen E Goings; Lieping Chen; Solomon Langermann; Stephen D Miller
Journal:  J Autoimmun       Date:  2013-05-14       Impact factor: 7.094

8.  Alterations in peripheral blood mononuclear cell cytokine production in response to phytohemagglutinin in multiple sclerosis patients.

Authors:  B Crucian; P Dunne; H Friedman; R Ragsdale; S Pross; R Widen
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

9.  The potential role of heat shock proteins in acute spinal cord injury.

Authors:  Yijun Zhou; Leilei Xu; Xinghua Song; Liwen Ding; Jiangtao Chen; Chong Wang; Yuling Gan; Xiaomeng Zhu; Yipin Yu; Qiuzhen Liang
Journal:  Eur Spine J       Date:  2014-02-06       Impact factor: 3.134

10.  Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides.

Authors:  T Tsuchida; K C Parker; R V Turner; H F McFarland; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.